Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-04510-2, published online 12 January 2022
The original version of this Article contained errors.
In Figure 2, panels (G), (H) and (I) were omitted. The original Figure 2 and accompanying legend appear below.
Staining pattern of MAGE-A6 expression (A–C) and MAGE-A11 expression (D–F) in bladder tissues. (A) Intermediate staining for both nuclear and cytoplasmic expressions in low-grade BC (pTa stage), (B) Strong staining for nuclear expression and intermediate staining for cytoplasmic expression in high-grade BC (pT1 stage), (C) MAGE-A6 expression in adjacent normal tissue, (D) Weak staining for both nuclear and cytoplasmic expressions in low-grade BC (pTa stage), (E) Strong staining for both nuclear and cytoplasmic expressions in high-grade BC (pT2 stage), (F) MAGE-A11 expression in adjacent non-tumoral tissue, (G) MAGE-A6 expression in liver tissue as a positive control, (H) MAGE-A11 expression in prostate tissue as a positive control, and (I) Staining of bladder tissue with a nonreactive antibody (anti-CD11b antibody, negative control). All images were taken at 400× magnification.
Similarly, in Figure 4, panels (C)–(H) and in Figure 5, panels (C) and (D) were omitted. The original Figures 4 and 5 and their accompanying legends appear below.
Survival analysis for MAGE-A6 expression (A–D) and MAGE-A11 (E–H) in BC patients (Kaplan–Meier analysis). The number of patients in the analyzed groups is as follows: For DSS in N6/L group: 93 (censored (C) = 78 and death (D) = 15) , N6/I: 21 (C = 15 and D = 6), N6/H: 85 (C = 66 and D = 19), C6/L: 38 (C = 31 and D = 7), C6/I: 107 (C = 80 and D = 27), and C6/H: 54 (C = 48 and D = 6). For PFS in N6/L group: 93 (C = 72 and D = 21), N6/I: 21 (C = 14 and D = 7), N6/H: 85 (C = 62 and D = 23), C6/L: 38 (C = 28 and D = 10), C6/I: 107 (C = 75 and D = 32), and C6/H: 54 (C = 45 and D = 9). For DSS in N11/L group: 172 (C = 135 and D = 37), N11/I: 25 (C = 22 and D = 3), N11/H:16 (C = 14 and D = 2), C11/L: 57 (C = 48 and D = 9), C11/I: 67 (C = 54 and D = 13), and C11/H: 89 (C = 69 and D = 20). For PFS in N11/L group: 172 (C = 125 and D = 47), N11/I: 25 (C = 21 and D = 4), N11/H: 16 (C = 14 and D = 2), C11/L:57 (C = 45 and D = 12), C11/I: 67 (C = 52 and D = 15), and C11/H: 89 (C = 63 and D = 26). C: cytoplasm, C6: cytoplasmic expression of MAGE-A6, C11: cytoplasmic expression of MAGE-A11, DSS: disease-specific survival, H: high expression, I: intermediate expression L: low expression, N: nuclear, N6: nuclear expression of MAGE-A6, N11: nuclear expression of MAGE-A11, P: p value, PFS: progression free-survival. Charts were drawn by Prism version 8.3.0 software (Graph Pad Inc., San Diego, CA, USA). https://www.graphpad.com/support/faq/prism-830-release-notes/.
Survival analysis for nuclear and cytoplasmic MAGE-A6/MAGE-A11 phenotypes. (A–D; Kaplan–Meier analysis). The number of patients in the analyzed groups is as follows: For DSS in N6/11–1 phenotype 49 (censored (C) = 40 and death (D ) = 9), N6/11–2: 67 (C = 49 and D = 18), N6/11–3: 21 (C = 19 and D = 2), N6/11–4: 21 (C = 17 and D = 4), C6/11–1: 23 (C = 19 and D = 4), and C6/11–2: 38 (C = 31 and D = 17), C6/11–3: 22 (C = 16 and D = 6) , and C6/11–4: 75 (C = 59 and D = 16) . For PFS in N6/11–1 phenotype 49 (C = 37 and D = 12), N6/11–2: 67 (C = 46 and D = 21), N6/11–3: 21 (C = 17 and D = 14), N6/11–4: 21 (C = 16 and D = 5), C6/11–1: 23 (C = 17 and D = 6), and C6/11–2: 38 (C = 30 and D = 8), C6/11–3: 22 (C = 16 and D = 6) , and C6/11–4: 75 (C = 53 and D = 22). C: cytoplasmic, C6/11: cytoplasmic expression of MAGE-A6 and MAGE-A11, DSS: disease-specific survival, N: nuclear, N6/11: nuclear expression of MAGE-A6 and MAGE-A11, P: p value, PFS: progression-free survival, 1: MAGE-A6low/MAGE-A11low phenotype, 2: MAGE-A6high/MAGE-A11low phenotype, 3: MAGE-A6low/MAGE-A11high phenotype, 4: MAGE-A6high/MAGE-A11high phenotype. Charts were drawn by Prism version 8.3.0 software (Graph Pad Inc., San Diego, CA, USA) https://www.graphpad.com/support/faq/prism-830-release-notes/.
Additionally, in Table 1, values in columns “Total samples N (%)”, “Nuclear expression of MAGE-A11” and “Cytoplasmic expression of MAGE-A11” were omitted. The original Table 1 and accompanying legend appear below.
Finally, the data in Table 2 did not display correctly. The original Table 2 and accompanying legend appear below.
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mohsenzadegan, M., Razmi, M., Vafaei, S. et al. Publisher Correction: Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer. Sci Rep 12, 2330 (2022). https://doi.org/10.1038/s41598-022-06282-9
Published:
DOI: https://doi.org/10.1038/s41598-022-06282-9
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
